ReviewFrontiers in allergy2026
Are we there yet? understanding interactions between respiratory viral infections, atopy, and the microbiome.
Review in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Atopic disease has become an increasingly prevalent condition worldwide and a significant health concern. Similarly, due to concerns about morbidity associated with respiratory viral illness in early childhood, there has been increased exploration of the relationship between atopy and viral illnesses. Historically, studies have focused on early-life respiratory infections driving the development of atopy or post-viral airway disease, with respiratory syncytial virus (RSV) infection driving post-viral disease in those without atopy, while human rhinovirus (hRV) leading to asthma in those with pre-existing atopy. The impact of atopy on the antiviral immune response remains debated, with some studies suggesting it provides a protective role, while others suggest it impairs the immune response. Beyond the respiratory tract, the gut microbiome increasingly is recognized as a potential modulator of both local and distant immune responses, a relationship associated with lung function termed the gut-lung axis. As we continue to elucidate the biochemical mechanisms underlying these pathways in mouse models, it will be important to identify analogous human pathways. This review explores what is currently known about the relationship between atopy and respiratory viral infections focusing on knowledge about how viral infections drive atopy and, reciprocally, how atopy modulates respiratory viral induced disease. Moreover, we review published information on analogous human pathways. Utilizing this information will help us with better disease management and potential development of targeted therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.